Alan Enciso

After completing his PhD at TCU, Alan conducted postdoctoral research in the laboratories of Nobel Prize candidate Krzysztof Matyjaszewski, followed by a second postdoctoral appointment in the laboratory of Nobel Laureate Fraser Stoddart. He then began his industrial career at Myris Therapeutics, where he worked on antibody–drug conjugates and earned his first patent. During the COVID pandemic, he joined Pfizer as a Senior Scientist in the Lipid Nanoparticles (LNPs) group, contributing to four patents in the vaccine space. He currently serves as a Principal Scientist at GSK in the Drug Product Vaccines department, continuing to advance lipid nanoparticle technologies.